Picton Mahoney Asset Management’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-37
Closed -$1.19K – 1660
2026
Q1
$1.19K Hold
37
– – ﹤0.01% 1116
2025
Q4
$1.56K Hold
37
– – ﹤0.01% 1001
2025
Q3
$1K Sell
37
-267,168
-100% -$7.66M ﹤0.01% 1042
2025
Q2
$7.22M Buy
267,205
+6,710
+3% +$194K 0.07% 231
2025
Q1
$7.72M Buy
260,495
+253,858
+3,825% +$9.68M 0.13% 158
2024
Q4
$263K Buy
6,637
+6,600
+17,838% +$250K 0.01% 329
2024
Q3
$1K Buy
+37
New +$1.04K ﹤0.01% 814

Other funds holding VCYT

Picton Mahoney Asset Management's VCYT Position: Q2 2026 in Review

Picton Mahoney Asset Management sold out of Veracyte (VCYT) in Q2 2026, closing a stake of 37 shares — an estimated $1.19K sold.

Picton Mahoney Asset Management first reported a position in VCYT in Q3 2024 and held it in 7 quarters. The position peaked at $7.72M in Q1 2025. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Picton Mahoney Asset Management reported no remaining Veracyte position as of Q2 2026 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 37 Veracyte shares in Q2 2026, an estimated $1.19K.
  • Picton Mahoney Asset Management first reported a position in Veracyte in Q3 2024 and held it in 7 quarters.
  • Picton Mahoney Asset Management's Veracyte position peaked at $7.72M in Q1 2025.
  • 370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.